Nephros Inc. (NASDAQ:NEPH) Short Interest Up 28.8% in March

Nephros Inc. (NASDAQ:NEPH) was the target of a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 5,414 shares, a growth of 28.8% from the February 26th total of 4,205 shares. Based on an average daily volume of 35,028 shares, the short-interest ratio is presently 0.2 days. Currently, 0.1% of the company’s stock are sold short.

Nephros Price Performance

Shares of NEPH opened at $2.89 on Monday. The business’s fifty day moving average price is $3.88 and its 200 day moving average price is $4.57. Nephros has a 12-month low of $1.64 and a 12-month high of $6.42. The stock has a market capitalization of $30.75 million, a PE ratio of 26.28 and a beta of 1.42.

Nephros (NASDAQ:NEPH) last released its earnings results on Thursday, March 12th. The company reported $0.01 earnings per share for the quarter, meeting the consensus estimate of $0.01. The firm had revenue of $4.73 million during the quarter, compared to analyst estimates of $4.45 million. Nephros had a net margin of 6.35% and a return on equity of 12.22%.

Institutional Investors Weigh In On Nephros

A number of institutional investors have recently modified their holdings of the business. Kestra Advisory Services LLC acquired a new stake in Nephros during the fourth quarter worth about $29,000. Dimensional Fund Advisors LP acquired a new position in Nephros in the third quarter valued at approximately $64,000. Heron Bay Capital Management bought a new position in shares of Nephros during the fourth quarter valued at approximately $66,000. Citadel Advisors LLC grew its holdings in shares of Nephros by 39.2% during the third quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock valued at $78,000 after purchasing an additional 4,655 shares during the last quarter. Finally, XTX Topco Ltd raised its position in shares of Nephros by 48.5% during the 4th quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock worth $105,000 after purchasing an additional 7,062 shares during the period. Institutional investors own 41.10% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Nephros in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $6.00.

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.